Australian researchers stopping melanoma in its tracks

Australian researchers stopping melanoma in its tracks

11 September 2017

A team of Australian researchers has made the ultimate move in the battle to beat melanoma, successfully trialling a combination of new treatments to stop the disease in its tracks and prevent it from spreading or metastasising to distant organs.

Melanoma is the deadliest form of skin cancer, with one Australian dying from advanced melanoma every five hours.

Ground-breaking results from two international clinical trials conducted by investigators at Melanoma Institute Australia are being presented today at one of the world’s largest medical oncology conferences, the European Society for Medical Oncology (ESMO) 2017 Congress in Spain. The research has also been published in the prestigious New England Journal of Medicine today.

The trials, COMBI-AD and CheckMate 238, proved successful in preventing the spread of disease in Stage III melanoma patients whose tumours had been surgically removed. Until now, these patients were at a high risk (40−70 per cent) of their disease progressing to advanced and fatal melanoma.

“These results will change the way we treat melanoma patients as well as their quality of life,” says study author Professor Georgina Long (pictured), Conjoint Medical Director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research at The University of Sydney. 

“Until now, Stage III melanoma patients who have had their tumours surgically removed have simply had to play the waiting game, to see if their melanoma would metastasise or spread. Living with such fear severely affected them and their loved ones.

“Results from these clinical trials suggest we can stop the disease in its tracks – effectively preventing it from spreading and saving lives. Our ultimate goal of making melanoma a chronic rather than a terminal illness is now so much closer to being achieved,” she said.

In the COMBI-AD trial, patients were randomised to receive a combination of targeted therapies (dabrafenib and trametinib) or placebo for 12 months. Targeted therapies block the action of a particular gene which is a driver for melanoma. It was aimed at patients who are BRAF positive. It not only prevented resected Stage III melanoma from recurring, but it increased overall survival.

The CheckMate 238 trial involved patients with high risk Stage III and Stage IV disease who had had all melanoma surgically removed. They were randomised to be treated with the immunotherapy nivolumab or ipilimumab for 12 months.  Immunotherapies reboot the immune system to attack the melanoma cells. Results showed nivolumab decreased the chance of relapse, and it had a superior safety profile over ipilimumab. This benefit was seen in patients regardless of BRAF mutation status. The follow up period is too short to yet determine long-term survival rates.

Research had already shown that targeted and immune therapies can successfully treat patients with advanced (Stage IV) melanoma that could not be removed surgically.

These clinical trials are the first in the world to give the treatments to melanoma patients at an earlier stage of the disease to prevent spread and recurrence.

“These clinical trials show we now have ammunition to prevent melanoma spreading and progressing, which until now was a critical area of disease behaviour where we had no control,” Professor Long said.

“This will change how melanoma is treated around the world, as we no longer have to passively wait to see if the melanoma spreads.

“We can now actively and effectively attack the melanoma at an earlier stage, reducing the dreadful anxiety for patients about progressing to a potentially terminal illness and ensuring they have much better outcomes,” she said.  

History teacher and mother Renae Aslanis was a patient on the COMBI-AD trial. After having 10 lymph nodes removed, she decided to enter the clinical trial rather than just "watching and waiting". Now four-and-a-half years later, she is still "going strong"! Read more.

Download the media release

Renae

Publications:

Australasian Melanoma Conference AMC2021
19 Nov - 20 Feb 2021

Australasian Melanoma Conference AMC2021

The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.

Sharing our knowledge of melanoma on the global stage
15 Apr 2021

Sharing our knowledge of melanoma on the global stage

As leaders in the field of melanoma, clinicians and researchers from MIA will be sharing their knowledge at the virtual 10th World Congress of Melanoma. 

Tags: melanoma
Community Fundraising Wrap Up Jan-Mar 2021
15 Apr 2021

Community Fundraising Wrap Up Jan-Mar 2021

The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.

Tags: melanoma
Melanoma patients and their families urged to speak up and put national spotlight on melanoma.
15 Apr 2021

Melanoma patients and their families urged to speak up and put national spotlight on melanoma.

Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.

Tags: melanoma
Support for Melanoma March has come from everywhere
12 Apr 2021

Support for Melanoma March has come from everywhere

We have been buoyed by the wonderful support for our Melanoma March campaign, and our mission to cover Australia in footprints continues into April!

An inspiring WA Melanoma Community Forum
26 Mar 2021

An inspiring WA Melanoma Community Forum

There was a wonderful feeling of community support amongst the melanoma patients, families and friends at the WA Melanoma Community Form. 

Tags: melanoma
Family of 8-year-old with melanoma calls on all Australians to step up to help save lives
26 Mar 2021

Family of 8-year-old with melanoma calls on all Australians to step up to help save lives

The Price family has decided to share their story to inspire Australians to support research into new melanoma treatments.

Tags: melanoma
Rethinking skin surveillance for high-risk melanoma patients
18 Mar 2021

Rethinking skin surveillance for high-risk melanoma patients

New research has provided evidence in favour of a structured skin surveillance program for high-risk melanoma patients.

Tags: melanoma
Australia's oldest melanoma survivor steps up to save lives on his 105th birthday
11 Mar 2021

Australia's oldest melanoma survivor steps up to save lives on his 105th birthday

Melanoma research saved Bert's life at 101 and now he wants to give back. 

Tags: melanoma
Predicting disease spread in thin melanoma
05 Mar 2021

Predicting disease spread in thin melanoma

A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.   

Tags: melanoma
Exploring our own clinical questions through MIA's new trials initiative
04 Mar 2021

Exploring our own clinical questions through MIA's new trials initiative

MIA has recently established a new division of our Clinical Trials Program which co-ordinates and manages investigator-led multi-centre trials. 

Tags: melanoma
Young researchers awarded Fellowships to pursue innovative treatments for melanoma
04 Mar 2021

Young researchers awarded Fellowships to pursue innovative treatments for melanoma

Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.

Tags: melanoma
Young researchers receive boost to develop innovative treatment for melanoma
04 Mar 2021

Young researchers receive boost to develop innovative treatment for melanoma

Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.

Tags: melanoma
Launch of Melanoma March 2021
01 Mar 2021

Launch of Melanoma March 2021

Aussies urged to leave their footprint on melanoma as efforts step up to save lives from the disease.

Tags: melanoma
Olivia Vivian announced as MIA ambassador
12 Feb 2021

Olivia Vivian announced as MIA ambassador

Olivia is using her Ninja star power to shine a spotlight on melanoma prevention - in memory of her dad. 

Tags: melanoma
Melanoma breakthrough - neoadjuvant treatment saving lives.
09 Feb 2021

Melanoma breakthrough - neoadjuvant treatment saving lives.

Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.

Tags: melanoma
Melanoma breakthrough - neoadjuvant therapy saving lives.
09 Feb 2021

Melanoma breakthrough - neoadjuvant therapy saving lives.

Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.

Tags: melanoma
Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
04 Feb 2021

Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?

New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.

Tags: melanoma
Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
04 Feb 2021

Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?

New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.

Tags: melanoma
A message to all Australians from melanoma patient Stuart Taylor
16 Dec 2020

A message to all Australians from melanoma patient Stuart Taylor

Stuart has advanced melanoma which is not responding to treatment. He has shared his story on ABC's 7:30 in the hope that others can escape the same fate. 

Tags: melanoma